Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Gene Therapy00:59

Gene Therapy

Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Myocarditis I: Introduction01:21

Myocarditis I: Introduction

Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to the letter: 'multimodality imaging in cardio-oncology: from detection to actionable management to the editor'.

European heart journal. Cardiovascular Imaging·2026
Same author

Beyond the Multidisciplinary Team: The Central Role of Nurses in Cardio-Oncology.

European journal of cardiovascular nursing·2026
Same author

Cardiovascular toxicity of breast cancer treatments: from understanding to enhancing survivorship care.

ESMO open·2025
Same author

Radiation Oncology Opinions and Practice on Cardiotoxicity in Lung Cancer: A Cross-sectional Study by the International Cardio-oncology Society.

Clinical oncology (Royal College of Radiologists (Great Britain))·2024
Same author

European Society of Cardiology quality indicators for the prevention and management of cancer therapy-related cardiovascular toxicity in cancer treatment.

European heart journal. Quality of care & clinical outcomes·2022
Same author

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Related Experiment Video

Updated: Jul 9, 2026

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

Gene therapy: targeting the myocardium.

A R Lyon1, M Sato, R J Hajjar

  • 1Department of Cardiac Medicine, National Heart and Lung Institute, Dovehouse Street, London, SW3 6LY, UK. a.lyon@ic.ac.uk

Heart (British Cardiac Society)
|December 18, 2007
PubMed
Summary

Gene therapy for heart disease is advancing with new bioengineered viral vectors. These tools improve gene delivery to the myocardium, enabling clinical trials for myocardial disease.

More Related Videos

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Related Experiment Videos

Last Updated: Jul 9, 2026

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model
06:03

Delivery of Modified mRNA in a Myocardial Infarction Mouse Model

Published on: June 11, 2020

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing
11:09

Generation of Aligned Functional Myocardial Tissue Through Microcontact Printing

Published on: March 19, 2013

Gene Transfer for Ischemic Heart Failure in a Preclinical Model
07:35

Gene Transfer for Ischemic Heart Failure in a Preclinical Model

Published on: May 15, 2011

Area of Science:

  • Cardiovascular Biology
  • Gene Therapy
  • Molecular Medicine

Background:

  • Effective gene therapy delivery to the heart is complex.
  • Myocardial targeting requires sophisticated biological system design.
  • Advancements in vectorology are crucial for cardiac gene therapy.

Purpose of the Study:

  • To review the progress of gene therapy for myocardial disease.
  • To highlight the role of bioengineered viral vectors in cardiac gene delivery.
  • To discuss the translation of cardiac gene therapy from preclinical models to clinical application.

Main Methods:

  • Review of literature on cardiac gene therapy.
  • Focus on bioengineered recombinant viral vectors for myocardial targeting.
  • Analysis of advances in genetic payload selection and design.

Main Results:

  • Bioengineered viral vectors enhance gene delivery efficiency to the myocardium.
  • Preclinical models demonstrate effective cardiac gene therapy.
  • New gene therapy trials for myocardial disease are emerging.

Conclusions:

  • Gene therapy holds significant promise for treating myocardial diseases.
  • Targeted viral vectors are key to successful clinical translation.
  • Ongoing clinical trials represent a new era for cardiac gene therapy.